サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1461171

抗炎症生物学的製剤の世界市場規模調査＆予測：薬剤クラス別、用途別、投与経路別、流通チャネル別、地域別分析、2023-2030年

Global Anti-Inflammatory Biologics Market Size Study & Forecast, by Drug Class, By Application, By Route of Administration, By Distribution Channel, and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 200 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.95円
抗炎症生物学的製剤の世界市場規模調査＆予測：薬剤クラス別、用途別、投与経路別、流通チャネル別、地域別分析、2023-2030年
出版日: 2024年03月22日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文 200 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗炎症生物学的製剤市場は、2022年に約931億3,000万米ドルと評価され、予測期間2023-2030年には5.9％以上の成長率で成長すると予測されています。

抗炎症生物学的製剤は、体内の炎症を標的にして抑えるように設計された先進的な医薬品で、主に乾癬、潰瘍性大腸炎、関節リウマチ、炎症性腸疾患などの治療に使用され、生物製剤の需要に拍車をかけています。生物学的製剤は、免疫系における特定の分子や経路に干渉することで作用し、症状の緩和や組織損傷の防止に役立ちます。これらの生物学的製剤は炎症性疾患の治療状況を一変させ、従来の治療法に反応しない患者に救済を提供しています。有利な償還政策、高齢化人口の増加、ヘルスケア支出の増加、炎症に対する意識の高まりは、世界中で市場の需要を促進している最も顕著な要因です。

さらに、乾癬、関節リウマチ、強直性脊椎炎、炎症性腸疾患、潰瘍性大腸炎などの自己免疫性炎症疾患の急増は、市場拡大を推進する極めて重要な要因です。例えば、NCBIが2021年8月に発表した研究では、米国の20歳以上の成人における乾癬の有病率は3％であると報告されており、この分野の勢いを裏付けています。同様に、2022年9月に発表されたNCBIの論文によれば、北欧州と北アメリカにおける関節リウマチの罹患率は、人口10万人当たりそれぞれ24人と36人でした。さらに、炎症性疾患の治療に生物学的製剤が迅速に採用され、生物学的療法に対する有利な償還状況が、市場の前進をさらに後押しする見通しです。さらに、生物学的製剤の開発のための研究活動への投資の増加やバイオテクノロジーの進歩は、予測期間中に様々な有利な機会をもたらします。しかし、抗炎症薬の副作用や、治療の第一選択薬としての生物学的製剤への関心の低さが、2023-2030年の予測期間を通じて市場成長の妨げとなっています。

抗炎症生物学的製剤の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、抗TNF薬に対する需要の急増と有望なパイプライン候補が市場成長を促進する主な要因となっているため、2022年に最大の市場シェアを獲得して市場を独占しました。さらに、主要企業の戦略的ポジショニングと同地域での医薬品販売の好調が、北米での市場拡大をさらに後押しすると予想されます。一方、アジア太平洋地域は予測期間中に最も急速な成長が見込まれます。多様な炎症性疾患の有病率の増加、ヘルスケア支出の増加、これらの疾患に対する利用可能な治療オプションに関する意識の高まりが、同地域全体の市場需要を大きく押し上げています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 抗炎症生物学的製剤の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 抗炎症生物学的製剤の世界市場力学

  • 抗炎症生物学的製剤市場の影響分析（2020～2030年）
    • 市場促進要因
      • 自己免疫性炎症疾患の急増
      • 有利な償還政策
    • 市場の課題
      • 抗炎症薬の副作用
      • 治療の第一選択薬としての生物学的製剤への関心の低さ
    • 市場機会
      • 生物学的製剤開発のための研究投資の増加
      • バイオテクノロジーの進歩

第4章 抗炎症生物学的製剤の世界市場：産業分析

  • ポーターのファイブフォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターのファイブフォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 抗炎症生物学的製剤の世界市場：薬剤クラス別

  • 市場スナップショット
  • 薬剤クラス別抗炎症生物学的製剤の世界市場、実績 - ポテンシャル分析
  • 薬剤クラス別抗炎症生物学的製剤の世界市場推定・予測：2020-2030年
  • 抗炎症生物学的製剤市場、サブセグメント分析
    • 抗腫瘍壊死因子（TNF）
    • インターロイキン拮抗薬
    • ヤヌスキナーゼ（JAK）阻害薬
    • その他

第6章 抗炎症生物学的製剤の世界市場：投与経路別

  • 市場スナップショット
  • 抗炎症生物学的製剤の世界市場：投与経路別、実績 - ポテンシャル分析
  • 抗炎症生物学的製剤の世界市場、投与ルート別推定・予測2020-2030年
  • 抗炎症生物学的製剤市場、サブセグメント分析
    • 経口剤
    • 注射剤

第7章 抗炎症生物学的製剤の世界市場：用途別

  • 市場スナップショット
  • 抗炎症生物学的製剤の世界市場：用途別、実績 - ポテンシャル分析
  • 抗炎症生物学的製剤の世界市場：用途別推定・予測2020～2030年
  • 抗炎症生物学的製剤市場、サブセグメント分析
    • 関節リウマチ
    • 乾癬
    • その他

第8章 抗炎症生物学的製剤市場：流通チャネル別

  • 市場スナップショット
  • 抗炎症生物学的製剤の世界市場：流通チャネル別、実績 - ポテンシャル分析
  • 抗炎症生物学的製剤の世界市場：流通チャネル別推定・予測2020～2030年
  • 抗炎症生物学的製剤市場、サブセグメント分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第9章 抗炎症生物学的製剤の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 抗炎症生物学的製剤市場の地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤クラス別推定・予測、2020-2030年
      • 投与経路の推定・予測、2020-2030年
      • アプリケーションの推定・予測、2020～2030年
      • 流通チャネルの推定・予測、2020-2030年
    • カナダ
  • 欧州抗炎症生物学的製剤市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋抗炎症生物学的製剤市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの抗炎症生物学的製剤市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第10章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • AbbVie Inc. (U.S.)
      • 主要情報
      • 概要
      • 財務情報（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • Merck & Co., Inc. (U.S.)
    • Bristol-Myers Squibb Company (U.S.)
    • Johnson & Johnson Services, Inc. (U.S.)
    • Pfizer Inc. (U.S.)
    • Novartis AG (Switzerland)
    • UCB S.A. (Belgium)
    • Eli Lilly and Company (U.S.)
    • Amgen Inc. (U.S.)
    • Biogen (U.S.)

第11章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1.Global Anti-Inflammatory Biologics Market, report scope
  • TABLE 2.Global Anti-Inflammatory Biologics Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3.Global Anti-Inflammatory Biologics Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
  • TABLE 4.Global Anti-Inflammatory Biologics Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 5.Global Anti-Inflammatory Biologics Market estimates & forecasts by Application 2020-2030 (USD Billion)
  • TABLE 6.Global Anti-Inflammatory Biologics Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 7.Global Anti-Inflammatory Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8.Global Anti-Inflammatory Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9.Global Anti-Inflammatory Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10.Global Anti-Inflammatory Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11.Global Anti-Inflammatory Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12.Global Anti-Inflammatory Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13.Global Anti-Inflammatory Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14.Global Anti-Inflammatory Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15.Global Anti-Inflammatory Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16.Global Anti-Inflammatory Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17.U.S. Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18.U.S. Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19.U.S. Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20.Canada Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21.Canada Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22.Canada Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23.UK Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24.UK Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25.UK Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26.Germany Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27.Germany Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28.Germany Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29.France Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30.France Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31.France Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32.Italy Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33.Italy Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34.Italy Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35.Spain Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36.Spain Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37.Spain Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38.RoE Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39.RoE Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40.RoE Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41.China Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42.China Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43.China Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44.India Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45.India Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46.India Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47.Japan Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48.Japan Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49.Japan Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50.South Korea Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51.South Korea Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52.South Korea Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53.Australia Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54.Australia Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55.Australia Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56.RoAPAC Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57.RoAPAC Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58.RoAPAC Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59.Brazil Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60.Brazil Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61.Brazil Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62.Mexico Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63.Mexico Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64.Mexico Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65.RoLA Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66.RoLA Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67.RoLA Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68.Saudi Arabia Anti-Inflammatory Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 69.South Africa Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70.RoMEA Anti-Inflammatory Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 71.List of secondary sources, used in the study of global Anti-Inflammatory Biologics Market
  • TABLE 72.List of primary sources, used in the study of global Anti-Inflammatory Biologics Market
  • TABLE 73.Years considered for the study
  • TABLE 74.Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1.Global Anti-Inflammatory Biologics Market, research methodology
  • FIG 2.Global Anti-Inflammatory Biologics Market, Market estimation techniques
  • FIG 3.Global Market size estimates & forecast methods
  • FIG 4.Global Anti-Inflammatory Biologics Market, key trends 2022
  • FIG 5.Global Anti-Inflammatory Biologics Market, growth prospects 2023-2030
  • FIG 6.Global Anti-Inflammatory Biologics Market, porters 5 force model
  • FIG 7.Global Anti-Inflammatory Biologics Market, pest analysis
  • FIG 8.Global Anti-Inflammatory Biologics Market, value chain analysis
  • FIG 9.Global Anti-Inflammatory Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10.Global Anti-Inflammatory Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11.Global Anti-Inflammatory Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12.Global Anti-Inflammatory Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13.Global Anti-Inflammatory Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14.Global Anti-Inflammatory Biologics Market, regional snapshot 2020 & 2030
  • FIG 15.North America Anti-Inflammatory Biologics Market 2020 & 2030 (USD Billion)
  • FIG 16.Europe Anti-Inflammatory Biologics Market 2020 & 2030 (USD Billion)
  • FIG 17.Asia pacific Anti-Inflammatory Biologics Market 2020 & 2030 (USD Billion)
  • FIG 18.Latin America Anti-Inflammatory Biologics Market 2020 & 2030 (USD Billion)
  • FIG 19.Middle East & Africa Anti-Inflammatory Biologics Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Anti-Inflammatory Biologics Market is valued approximately at USD 93.13 billion in 2022 and is anticipated to grow with a growth rate of more than 5.9% over the forecast period 2023-2030. Anti-inflammatory biologics are advanced medications designed to target and reduce inflammation in the body, primarily used for treating conditions such as psoriasis, ulcerative colitis, rheumatoid arthritis and inflammatory bowel diseases has spurred demand for biologics. They work by interfering with specific molecules or pathways in the immune system, helping alleviate symptoms and prevent tissue damage. These biologics have transformed the treatment landscape for inflammatory conditions, offering relief to patients unresponsive to traditional therapies. The favorable reimbursement policies, rising aging population, increasing healthcare expenditure, and increased awareness of inflammation's are the most prominent factors that are propelling the market demand across the globe.

In addition, the surge in autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, and ulcerative colitis is a pivotal driver propelling market expansion. For instance, a study released by the NCBI in August 2021 reported a 3% prevalence of psoriasis among adults aged 20 years or older in the U.S., underlining the momentum in this arena. Likewise, according to the NCBI article published in September 2022, the incidence of rheumatoid arthritis in Northern Europe and Northern America was 24 and 36 cases per 100,000 people, respectively. Moreover, the swift adoption of biologics for treating inflammatory diseases and the favorable reimbursement landscape for biological therapies are poised to further bolster market advancement. Furthermore, the rise in investment in research activities for the development of biologics, as well as the growing advancements is biotechnology presents various lucrative opportunities over the forecasting years. However, the side effects of anti-inflammatory drugs and the lack of inclination for biologics as first line of treatment are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Anti-Inflammatory Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the surge in demand for anti-TNF drugs and promising pipeline candidates, serving as primary drivers propelling market growth. Furthermore, the strategic positioning of key players and robust sales of their pharmaceuticals in the region are anticipated to further bolster market expansion in North America. Whereas, Asia Pacific region is expected to grow the fastest over the forecast years. The increasing prevalence of diverse inflammatory disorders, rising healthcare spendings, and growing awareness regarding the available treatment options for these conditions are significantly propelling the market demand across the region.

Major market players included in this report are:

  • AbbVie Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Novartis AG (Switzerland)
  • UCB S.A. (Belgium)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Biogen (U.S.)

Recent Developments in the Market:

  • In February 2023, Pfizer Inc. revealed that the U.S. Food and Drug Administration (FDA) granted approval to its supplemental New Drug Application (sNDA) for CIBINQO, intended for patients grappling with moderate-to-severe atopic dermatitis.
  • In March 2022, AbbVie announced the approval of RINVOQ (upadacitinib) by the U.S. Food and Drug Administration (FDA) for treating adults diagnosed with ulcerative colitis.
  • In September 2022, Bristol Myers Squibb reported the two-year outcomes from the POETYK PSO Long-Term Extension (LTE) trial, focusing on sustained Sotyktu treatment in adult patients diagnosed with plaque psoriasis.
  • In October 2022, GSK plc offered insights into the ContRAst phase III program concerning otilimab, an investigational monoclonal antibody aimed at potentially treating moderate to severe rheumatoid arthritis.

Global Anti-Inflammatory Biologics Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Drug Class, Route of Administration, Application, Distribution Channel, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

  • Anti-Tumor Necrosis Factor (TNF)
  • Interleukins Antagonists
  • Janus Kinase (JAK) Inhibitors
  • Others

By Route of Administration:

  • Oral
  • Injection

By Application:

  • Rheumatoid Arthritis
  • Psoriasis
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

  • 1.1.Market Snapshot
  • 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1.Anti-Inflammatory Biologics Market, by region, 2020-2030 (USD Billion)
    • 1.2.2.Anti-Inflammatory Biologics Market, by Drug Class, 2020-2030 (USD Billion)
    • 1.2.3.Anti-Inflammatory Biologics Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.4.Anti-Inflammatory Biologics Market, by Application, 2020-2030 (USD Billion)
    • 1.2.5.Anti-Inflammatory Biologics Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3.Key Trends
  • 1.4.Estimation Methodology
  • 1.5.Research Assumption

Chapter 2.Global Anti-Inflammatory Biologics Market Definition and Scope

  • 2.1.Objective of the Study
  • 2.2.Market Definition & Scope
    • 2.2.1.Industry Evolution
    • 2.2.2.Scope of the Study
  • 2.3.Years Considered for the Study
  • 2.4.Currency Conversion Rates

Chapter 3.Global Anti-Inflammatory Biologics Market Dynamics

  • 3.1.Anti-Inflammatory Biologics Market Impact Analysis (2020-2030)
    • 3.1.1.Market Drivers
      • 3.1.1.1.Surge in the number of autoimmune inflammatory conditions
      • 3.1.1.2.Favourable reimbursement policies
    • 3.1.2.Market Challenges
      • 3.1.2.1.Side effects of anti-inflammtory drugs
      • 3.1.2.2.Lack of inclination for biologics as first line of treatment
    • 3.1.3.Market Opportunities
      • 3.1.3.1.Rise in investment in research activities for development of biologics
      • 3.1.3.2.Growing advancements is biotechnology

Chapter 4.Global Anti-Inflammatory Biologics Market: Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
  • 4.2.Porter's 5 Force Impact Analysis
  • 4.3.PEST Analysis
    • 4.3.1.Political
    • 4.3.2.Economical
    • 4.3.3.Social
    • 4.3.4.Technological
    • 4.3.5.Environmental
    • 4.3.6.Legal
  • 4.4.Top investment opportunity
  • 4.5.Top winning strategies
  • 4.6.COVID-19 Impact Analysis
  • 4.7.Disruptive Trends
  • 4.8.Industry Expert Perspective
  • 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Anti-Inflammatory Biologics Market, by Drug Class

  • 5.1.Market Snapshot
  • 5.2.Global Anti-Inflammatory Biologics Market by Drug Class, Performance - Potential Analysis
  • 5.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
  • 5.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
    • 5.4.1.Anti-Tumor Necrosis Factor (TNF)
    • 5.4.2.Interleukins Antagonists
    • 5.4.3.Janus Kinase (JAK) Inhibitors
    • 5.4.4.Others

Chapter 6.Global Anti-Inflammatory Biologics Market, by Route of Administration

  • 6.1.Market Snapshot
  • 6.2.Global Anti-Inflammatory Biologics Market by Route of Administration, Performance - Potential Analysis
  • 6.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 6.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
    • 6.4.1.Oral
    • 6.4.2.Injection

Chapter 7.Global Anti-Inflammatory Biologics Market, by Application

  • 7.1.Market Snapshot
  • 7.2.Global Anti-Inflammatory Biologics Market by Application, Performance - Potential Analysis
  • 7.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 7.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
    • 7.4.1.Rheumatoid Arthritis
    • 7.4.2.Psoriasis
    • 7.4.3.Others

Chapter 8.Anti-Inflammatory Biologics Market, by Distribution Channel

  • 8.1.Market Snapshot
  • 8.2.Global Anti-Inflammatory Biologics Market by Distribution Channel, Performance - Potential Analysis
  • 8.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 8.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
    • 8.4.1.Hospital Pharmacy
    • 8.4.2.Retail Pharmacy
    • 8.4.3.Online Pharmacy

Chapter 9.Global Anti-Inflammatory Biologics Market, Regional Analysis

  • 9.1.Top Leading Countries
  • 9.2.Top Emerging Countries
  • 9.3.Anti-Inflammatory Biologics Market, Regional Market Snapshot
  • 9.4.North America Anti-Inflammatory Biologics Market
    • 9.4.1.U.S. Anti-Inflammatory Biologics Market
      • 9.4.1.1.Drug Class breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2.Route of Administration breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3.Application breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4.Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 9.4.2.Canada Anti-Inflammatory Biologics Market
  • 9.5.Europe Anti-Inflammatory Biologics Market Snapshot
    • 9.5.1.U.K. Anti-Inflammatory Biologics Market
    • 9.5.2.Germany Anti-Inflammatory Biologics Market
    • 9.5.3.France Anti-Inflammatory Biologics Market
    • 9.5.4.Spain Anti-Inflammatory Biologics Market
    • 9.5.5.Italy Anti-Inflammatory Biologics Market
    • 9.5.6.Rest of Europe Anti-Inflammatory Biologics Market
  • 9.6.Asia-Pacific Anti-Inflammatory Biologics Market Snapshot
    • 9.6.1.China Anti-Inflammatory Biologics Market
    • 9.6.2.India Anti-Inflammatory Biologics Market
    • 9.6.3.Japan Anti-Inflammatory Biologics Market
    • 9.6.4.Australia Anti-Inflammatory Biologics Market
    • 9.6.5.South Korea Anti-Inflammatory Biologics Market
    • 9.6.6.Rest of Asia Pacific Anti-Inflammatory Biologics Market
  • 9.7.Latin America Anti-Inflammatory Biologics Market Snapshot
    • 9.7.1.Brazil Anti-Inflammatory Biologics Market
    • 9.7.2.Mexico Anti-Inflammatory Biologics Market
  • 9.8.Middle East & Africa Anti-Inflammatory Biologics Market
    • 9.8.1.Saudi Arabia Anti-Inflammatory Biologics Market
    • 9.8.2.South Africa Anti-Inflammatory Biologics Market
    • 9.8.3.Rest of Middle East & Africa Anti-Inflammatory Biologics Market

Chapter 10.Competitive Intelligence

  • 10.1.Key Company SWOT Analysis
  • 10.2.Top Market Strategies
  • 10.3.Company Profiles
    • 10.3.1.AbbVie Inc. (U.S.)
      • 10.3.1.1.Key Information
      • 10.3.1.2.Overview
      • 10.3.1.3.Financial (Subject to Data Availability)
      • 10.3.1.4.Product Summary
      • 10.3.1.5.Recent Developments
    • 10.3.2.Merck & Co., Inc. (U.S.)
    • 10.3.3.Bristol-Myers Squibb Company (U.S.)
    • 10.3.4.Johnson & Johnson Services, Inc. (U.S.)
    • 10.3.5.Pfizer Inc. (U.S.)
    • 10.3.6.Novartis AG (Switzerland)
    • 10.3.7.UCB S.A. (Belgium)
    • 10.3.8.Eli Lilly and Company (U.S.)
    • 10.3.9.Amgen Inc. (U.S.)
    • 10.3.10.Biogen (U.S.)

Chapter 11.Research Process

  • 11.1.Research Process
    • 11.1.1.Data Mining
    • 11.1.2.Analysis
    • 11.1.3.Market Estimation
    • 11.1.4.Validation
    • 11.1.5.Publishing
  • 11.2.Research Attributes
  • 11.3.Research Assumption